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ABSTRACT
 )CAS(  يتابسلا  نايرشلا  تاماعد  جئاتن  ةعجارم   :فادهلأا
.)CEA( يتابسلا نايرشلا ةنطاب لاصئتساو
 نيذلا  ىضرلما  نم  ةيبطلا  تلاجسلا  مييقتب  انمق   :ةقيرطلا
 ةرتفلا  للاخ ،يتابسلا  نايرشلا  يعوتلا  ةداعإ  تاءارجلإ نوعضخي
 ،ةرقنأ  ،تنكساب  ةعماج  ىفشتسم  يف  م2013  و  م2001  نم
 يف CEA تاءارجإ وأ يتابسلا نايرشلا تاماعدلا تيرجأ .ايكرت
 ضارعأ  نودب  يتابسلا  نايرشلا  قيضت  نم  نوناعي  نيذلا  ىضرلما
 تانايبلا  ليجست  تم  .)50%≥(  ضارعأب  قيضت  وأ  )70%≥(
 سيياقم تناك .ةيريرسلا جئاتنلاو ،ءارجلإا ليصافتو ةيفارغويمدلا
 تامجه  /  ةيغامدلا  ةتكسلا  اموي  30  ةدم  يف  ةيلولأا  جئاتنلا
 تضرفو  .تولما  وأ  يئزج  ىمعب  ةرباع  /  )TIA(  ةرباع  ةيغامد
 ةدمو فيزنلا تافعاضم و ،بصعلا ةباصإو ةيوناثلا جئاتن تاءارجا
 ICA( قيضتلا  ةدوعو ،ةيغامدلا  ةتكسلاو ،ىفشتسلما يف ةماقلإا
.ةليوط ةعباتلما ةرتف للاخ تولما بابسلأا عيمجو ،)حابلما
 قيضتل  CAS  تاءارجإ  115  و  CEA  194  تيرجأ   :جئاتنلا
 تاذ قورف دجوت لا .ضارعأ نودب وأ /و ضارعأب يتابسلا نايرشلا
 CAS ينب يبصعلا للاتعلااو ًاموي 30 ةدلم تايفو ةيئاصحإ ةللاد
 ىفشتسلما يف ةماقلإا ةدم تناك .CEA 7.7% تاءارجلإاو ،13%
 دعب ام ةلحرم يف .CEA p=0.001 ةعومجلما يف اريثك لوطأ ةرتفل
 ناكو ،ضارعأ  نم نوناعي  نيذلا  ىضرلما  يف  طقف  ،ةعباتم  يئارجإ
 نأ  لاإ  .CEA p=.045  ةعومجلما  يف  ىلعأ  قيضتلا  ةدوع  لدعم
.ًاريبك ًافلاتخا فلتخت لا ىرخلأا ةياهنلا
 نايرشلا ينيارشلا بلصت ضرم نم فللا ةماعدلا جلاعلا  :ةتمالخا
 ةبسنلاب  ةصاخو  ،ةيومدلا  ةيعولأا  ةحارلج  ليدب  وه  يتابسلا
 ريوطتو ،ةدايز ةبرتج .CEA رايعملل ريبك رطخ يه يتلا ىضرملل
 CAS ديزت ةديدلجا جلاعلا تلاوكوتوربو ةيغامدلا ةياملحا ةمظنأ
.ىودج
Objective: To review our results of carotid artery 
stenting (CAS) and carotid endarterectomy (CEA). 
Methods: We evaluated the medical records of 
patients undergoing carotid artery revascularization 
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procedure, between 2001 and 2013 in Baskent 
University Hospital, Ankara, Turkey. Carotid artery 
stenting or CEA procedures were performed in 
patients with asymptomatic carotid stenosis (≥70%) 
or symptomatic stenosis (≥50%). Demographic 
data, procedural details, and clinical outcomes were 
recorded. Primary outcome measures were in 30-day 
stroke/transient ischemic attacks (TIA)/amaurosis 
fugax or death. Secondary outcome measures were 
nerve injury, bleeding complications, length of stay 
in hospital, stroke, restenosis (ICA patency), and all-
cause death during long-term follow-up.
Results: One hundred ninety-four CEA and 115 
CAS procedures were performed for symptomatic 
and/or asymptomatic carotid artery stenosis. There 
is no significant differences 30-day mortality and 
neurologic morbidity between CAS (13%) and CEA 
procedures (7.7%). Length of stay in hospital were 
significantly longer in CEA group (p=0.001). In 
the post-procedural follow up, only in symptomatic 
patients, restenosis rate was higher in the CEA 
group (p=.045). The other endpoints did not differ 
significantly. 
Conclusions: Endovascular stent treatment of carotid 
artery atherosclerotic disease is an alternative for 
vascular surgery, especially for patients that are high 
risk for standard CEA. The increasing experience, 
development of cerebral protection systems and new 
treatment protocols increases CAS feasibility.
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Carotid artery stenosis being one of the leading causes of cerebrovascular diseases, is responsible for 
20-25% of all strokes.1 The superiority of surgical therapy 
to medical therapy has already been proved in severe 
carotid artery stenosis (>70%) by large-scale studies 
on symptomatic and asymptomatic patients; including 
North American Symptomatic Carotid Endarterectomy 
Trial (NASCET),2 European Carotid Surgery Trial,3 and 
Asymptomatic Carotid Atherosclerosis Study.4 With 
the advent of endovascular techniques, carotid artery 
stenting (CAS) has emerged as an alternative to surgery 
for the treatment of severe carotid artery stenosis in 
1990s.5 In randomized studies comparing 2 procedures; 
no significant difference was determined in terms of 
primary endpoints such as myocardial infarction (MI), 
stroke, death, or ipsilateral stroke in a 4-year period.6 
After the Carotid Revascularization Endarterectomy 
versus Stenting Trial (CREST) study has shown that 
CAS is non-inferior to carotid endarterectomy (CEA) 
in terms of primary outcomes, the number of patients 
treated with endovascular therapy has increased.6-8 In 
this study, the short- and long-term clinical outcomes 
and restenosis rates of CAS and CEA procedures carried 
out at our center were compared in patients with 
asymptomatic and symptomatic carotid artery stenosis.
Methods. This study included a total of 284 patients 
retrospectively, who underwent CEA or CAS for 
atherosclerotic stenosis in extracranial segments of carotid 
artery system in Baskent University hospital, Ankara 
from 2001 to 2013. Decision to proceed with CAS or 
CEA was based on the clinical evaluations performed by 
the departments of neurology, interventional radiology, 
and cardiovascular surgery and patient’s age, anatomic 
localization and severity of stenosis, symptom status, 
and comorbid conditions were taken into account. If 
the patient found to be eligible for both procedures, 
potential benefits and risks were explained in detail to 
patients and their relatives and the decisions as to which 
technique would be applied was made jointly with the 
patients and their relatives. As patient selection was 
retrospectively performed, no randomization between 
the 2 techniques could be performed. Either CEA or 
CAS performed angiographically for symptomatic 
internal carotid artery (ICA) stenosis of 50%  and 
asymptomatic stenosis >70% were included, in this 
single center. Patients with totally stenosed ICA were 
excluded from CAS and CEA procedures.
Medical files of the patients obtained from the 
hospital archives was examined and the data including 
demographic properties such as age, gender; comorbid 
disorders including hypertension (HT), coronary artery 
disease (CAD), diabetes mellitus (DM), peripheral 
arterial disease (PAD), previous stroke, hyperlipidemia, 
and smoking; neurological symptom status related to 
carotid artery disease; severity of carotid artery stenosis; 
postoperative complications; new vascular events 
during follow-up; and restenosis of the target vessel was 
recorded.
The patients were categorized into 2 groups based 
on symptom status; patients with amaurosis fugax, 
stroke, transient ischemic attack (TIA), syncope and/
or vertigo associated with carotid artery stenosis were 
considered as symptomatic, while patients without 
neurological symptoms were considered asymptomatic. 
Severity of carotid artery stenosis was determined by 
Carotid Doppler Ultrasonography (CDUS) according 
to Washington Criteria, Computed Tomography 
Angiography (CTA), Magnetic Resonance Angiography 
(MRA), and Digital Subtraction Angiography (DSA). 
Severity of carotid artery stenosis was measured by 
conventional angiography as previously described in 
NASCET study.9 A stenosis of 50% or greater was 
intervened in symptomatic cases and a stenosis of 70% 
or greater in asymptomatic cases.
Carotid artery stenting was performed by 2 
interventional radiologists with procedural experience 
of more than 15 previous carotid stenting procedures. 
During these procedures, cerebral protection 
techniques employing filter systems (Spider TM, Ev3 
Inc., Plymouth, MN, USA) were used in 111 cases; no 
embolic protection device was used in 4 cases due to the 
unavailability of those systems at the time of procedure. 
Carotid endarterectomy was performed under regional 
or local anesthesia by 2 separate cardiovascular 
surgeons with an operative experience of >15 previous 
endarterectomy procedures. Surgical procedures 
performed included primary repair, patch angioplasty, 
and eversion endarterectomy. 
Data on major complications such as mortality, 
stroke/TIA/amaurosis fugax, and hyperperfusion 
syndrome and the minor complications such as local 
hematoma and nerve injury within 1-month period after 
the procedure were accessed from the medical records. 
The long-term rates of mortality, stroke/TIA/amaurosis 
fugax, and restenosis were reviewed. The medical data of 
patients attending regular control visits were obtained 
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from patient records. Patients with no long-term 
follow-up after the procedure were called and invited 
to hospital for control visits. Patients attending control 
visits were questioned for complications, physically 
examined, and examined with CDUS for restenosis. All 
patients attending control visits gave written informed 
consent. 
Study data were analyzed based on the definitions 
below: Mortality was defined as death from any cause; 
TIA was defined as a newly developed neurological 
deficit that recovers within 24 hours; stroke was defined 
as neurological deficit lasting for more than 24 hours and/
or the presence of a lesion on the side of the procedure, 
with incresed diffusion on diffusion weighted sequences 
and decreased signal on apparent diffusion coefficient 
(ADC) sequences on MRI. Stroke, TIA, and amaurosis 
fugax on the same side as a procedure were defined as 
vascular complications.
First 30 days after the procedure were defined 
as the short-term and beyond 30 days as the ‘long-
term’. A stenosis of more than 50% (symptomatic 
and asymptomatic ) or total occlusion in CDUS was 
defined as restenosis. This study was approved by the 
Baskent University Institutional review Board and 
Ethics Committee (Project No: KA 13/197) and was 
supported by the Baskent University Research Fund.
Statistical analysis. Statistical analyses were 
performed with IBM SPSS for Windows Version 21.0 
(SPSS Inc., Chicago, IL, USA). Numeric variables were 
expressed as mean±standard deviation and median 
(min-max); categorical variables were expressed as 
number and percentage. Parametric test assumptions 
(normality of distribution and homogeneity of 
variances) were checked before statistical comparisons 
were made. Inter-group differences between numeric 
variables between 2 independent groups were tested 
with independent samples t test when parametric test 
assumptions were met and with Mann Whitney-U test 
otherwise. Categorical variables were compared between 
the groups using Chi-square test or Fisher’s exact test. 
A p-value of less than 0.05 was considered statistically 
significant.
Results. The study included 176 patients 
undergoing carotid endarterectomy and 108 patients 
undergoing CAS, totaling 284 patients with a total 
of 309 intervened vessels (194 endarterectomy, 115 
stent implantation). In the CEA group, 18 patients 
underwent bilateral intervention in separate sessions, 
while bilateral intervention was applied in separate 
sessions to 6 patients and in the same session to 1 
patient in the CAS group.
The mean age of the CEA and CAS groups were 
68.5±7.8 (49-86) years and 68.6±8.7 (41-84) years, 
respectively. Of 176 patients who underwent CEA, 
138 (78.4%) were male; 76 (70.3%) of 108 patients 
who underwent CAS were male. The two groups were 
not significantly different with respect to age (p=0.914) 
and gender (p=0.178). The demographic and clinical 
properties of the patients were summarized on Table 1. 
Hyperlipidemia (p<0.001), peripheral artery disease 
(p=0.007), and smoking (p=0.002) were significantly 
more common in the CEA group than the CAS group. 
In addition, there were significantly more asymptomatic 
patients in the CEA group compared with the CAS 
group (p<0.001). In symptomatic patients, the time 
from the onset of symptoms to the procedure was less 
Table 1 - Clinical and demographic features of patients between CEA 
and CAS.
Clinical and demographic 
characteristics
CEA (n=194) CAS (n=115) P-value
n (%)
<70 years 103 (53) 59 (51.3)
DiabetesMellitus 81 (41.8) 54 (47)   0.373
Hypertension 165 (85.1) 91 (79.1)   0.182
Coronary Artery Disease 122 (62.9) 60 (52.2)   0.064
Hyperlipidemia 134 (69.1) 51 (44.3) <0.001
Smoking 84 (43.3) 38 (33)   0.002
Asymptomatic 94 (48.5) 20 (17.4) <0.001
Symptomatic 100 (51.5) 95 (82.6) <0.001
Stroke 55 (28.3) 55 (47.8)
Transient Ischemic Attack 13 (6.7) 17 (14.8)
Amaurosis fugax 10 (5.1) 10 (8.7)
Vertigo 17 (8.8) 7 (6.1)
Syncope 5 (2.6) 6 (5.2)
Stenosis   0.983
50-70% 7 (3.6) 5 (4.3)
≥70% 187 (96.4) 110 (95.7)
CEA - carotid endarterectomy, CAS - carotid artery stenting
Table 2 - Comparison of the short-term complications between CEA 
and CAS.
Complications CEA 
(n=194)
CAS 
(n=115)
P-value
n (%)
Short-term complications 24 (12.4) 21 (18.3) 0.211
Stroke/TIA/Amaurozis fugax 15 (7.7) 15 (13) 0.185
-
-
-
-
-
Local hematoma 9 (4.6) 2 (1.7)
Nerve injury 1 (0.5) -
Exitus 2 (1) -
Bradykardia/hypotension 1 (0.5) 2 (1.7)
Intracranial hematoma - 2 (1.7)
Myocardial infarction - - -
CEA - carotid endarterectomy, CAS - carotid artery stenting
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than 1 month in 59 (63.4%) patients in the CEA group 
and 65 (71.4%) in the CAS group (p=0.248).
The analysis of CEA and CAS groups for short-term 
complications revealed no significant difference between 
the 2 (Table 2). Clinical presentation (asymptomatic 
vs symptomatic) and age (<70 years vs ≥70 years) did 
not significantly affect early vascular events (Table 3). 
Deaths in the CEA group occurred from heart failure in 
one patient and from stroke secondary to the occlusion 
of the target artery at the first postoperative day in the 
other. 
The mean duration of hospital stay was 5.9±5.8 days 
in the CEA group and 4.5±4.4 days in the CAS group. 
The shortness of hospital stay duration in CAS group 
was statistically significant (p<0.001). One hundred and 
thirty (67%) patients in the CEA group and 86 (74.8%) 
patients in the CAS group had long-term neurological 
examinations and CDUS tests. All other patients were 
invited to attend follow-up visits via telephone but 
some of them refused to do so while some others had 
died before. It was learned from patient relatives that 
18 (10.3%) patients in the CEA group and 6 (5.5%) 
patients in the CAS group died during follow-up, but 
the exact cause of death could not be learned as the 
interviews were done via telephone. Death rate was not 
significantly different between the 2 groups (p=0.288).
In the CEA group with follow-up information, 
the mean follow-up duration was 24.4±23.7 (1-105) 
months while it was 17.1±23.4 (1-120) months in the 
CAS group (p=0.003). The analysis of the long-term 
complications of the patients with available follow-up 
data revealed that 4 (4.7%) in the CAS group and 9 
(6.9%) in the CEA group developed ipsilateral stroke, 
TIA, and amaurosis fugax. No significant difference 
was observed between long-term complications in both 
groups (p=0.693). A subgroup analysis based on clinical 
presentation and age did not reveal any significant 
difference with regard to vascular complications 
(Table 4, Table 5). 
Nineteen (14.6%) patients in the CEA group and 6 
(7%) patients in the CAS group developed target vessel 
restenosis. The restenosis rate was higher in the CEA group 
compared with the CAS group, although the difference 
was not statistically significant (p=0.133). There were 
non-significant correlations between restenosis rate and 
HT (p=0.3), HL (p=0.9), DM (p=0.5), CAD (p=0.4), 
and smoking (p=0.5). A subgroup analysis based on 
clinical presentation indicated a significantly higher 
restenosis rate in symptomatic patients undergoing 
CEA than those undergoing CAS (p=0.045) (Table 4). A 
subgroup analysis by age showed that restenosis rate was 
higher in patients younger than 70 years in the CEA 
group compared with the patients of the same age in 
the CAS group, although that difference did not reach 
statistical significance (Table 5).
Discussion. Carotis artery stenting was first used 
for patients at high risk for CEA and has been shown 
that it may be efficiently and safely used for this group 
of patients.10 Randomized studies comparing CAS and 
CEA have reported similar short-term rates of stroke, 
Table 3 - The relation of vascular complication with clinical presentation 
and patient age.
 
Complications Short-term stroke/TIA/amaurosis fugax p-value
CEA CAS 
n (%)
Asymptomatic 4/94 (4.3) 1/20 (5) 1.000
Symptomatic 11/100 (11) 14/95 (14.7) 0.571
<70 years 7/103 (6.8) 5/59 (8.5) 0.759
≥70 years 8/91 (8.8) 10/56 (17.9) 0.171
n - no of complication/no of patients, CEA - carotid endarterectomy, 
CAS - carotid artery stenting
Table 4 - The relation of long-term vascular complication and restenosis rate with clinical presentation.
Complications Asymptomatic
p-value
Symptomatic
p-value
CEA(n=63) CAS(n=18) CEA(n=67) CAS(n=68)
Long-term vascular complication 3 (4.8) 2 (11.1) 0.307 6 (9) 2 (2.9) 0.165
Restenosis 8 (12.7) 3 (16.7) 0.701 11 (16.4) 3 (4.4) 0.045
CEA - carotid endarterectomy, CAS - carotid artery stenting
Table 5 - The relation of long-term vascular complication and restenosis rate with age.
Complications <70 ≥70
CEA(n=70) CAS(n=47) p-value CEA(n=60) CAS(n=39) p-value
Long-term vascular complication 4 (5.7%) 2 (4.3%) 1.000 5 (8.3%) 2 (5.1%) 0.701
Restenosis 14 (20%) 3 (6.4%) 0.075 5 (8.3%) 3 (7.7%) 1.000
CEA - carotid endarterectomy, CAS - carotid artery stenting
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symptomatic ones.10 Our study, in compliance with the 
literature, found a higher rate of vascular complications 
within 30 days in symptomatic cases compared with 
asymptomatic ones in both the CAS and CEA groups.10 
Carotid Stenting Trialists Colloboration (CSTC) 
meta-analysis comprising 3433 patients enrolled in 
EVA-3S, SPACE, and ICSS studies demonstrated that 
stroke and death were significantly higher in the CAS 
group than the CEA group in the first 120 days after the 
procedure, but the difference between the 2 procedures 
was related to the patient age at the time of procedure. 
According to that meta-analysis, rates of death and 
stroke within the first 120 days were the same in CAS 
5.8% and CEA groups 5.7% in patients below the age 
of 70 years, but they were two-fold higher in the CAS 
group above the age of 70 years 12% for the CAS group 
versus 5.9% for the CEA group.23 Similarly, CREST 
study found that CAS was more beneficial with respect 
to primary endpoints at the periprocedural period 
including stroke, MI, and death for patients below 
the age of 70 years while CEA was more beneficial for 
those older than 70 years.6 Our study included a total 
of 147 cases above the age of 70. Short-term vascular 
complications were similar between CAS 6.8% and 
CEA 8.5% in those who were below the age of 70 years, 
while they were more frequent in the CAS group when 
the patients got older than 70 years, as reported in the 
literature. We did not find any difference between the 
group’s long-term complications with respect to the 
patient age at the time of procedure in either group.
Local hematoma and cranial nerve injury, which are 
among perioperative complications, have been reported 
more frequently with CEA than CAS,11,24 and our 
results were in compliance with literature results. Intra-
procedural and post-procedural complications may 
lengthen duration of hospital stay with concomitant 
increase in treatment costs. In our study, duration 
of hospital stay was significantly shorter in the CAS 
group (p<0.001), as reported elsewhere.11 Although 
procedural complications are slightly more frequent at 
the periprocedural period with CAS, long-term rates of 
mortality and stroke were similar between CAS and CEA 
procedures.6,25-27 We also found that the long-term rates 
of stroke and death were similar in patients undergoing 
CAS or CEA, in compliance with the literature. 
Restenosis in the target vessel may affect treatment 
success. In some studies, restenosis has been defined 
as stenosis of 50% or greater, and in some others, 
70% or greater.25,28,29 Not every stenosis leads to new 
neurological problems; studies have reported restenosis 
rates varying between 6% and 14%, although only 1-5% 
of these cases have reported to suffer a new neurological 
MI, and mortality and long-term rate of ipsilateral 
stroke.8,11 CAS is now recommended as an alternative 
to CEA in severely symptomatic carotid artery stenosis 
and in selected asymptomatic patients.12 
It has been suggested that operator’s experience, his/
her medical branch, and patient selection criteria 
may influence complication rates of CEA and 
CAS.13-15 Therefore, success and complication rates may 
differ between centers.
In our study, the rates of 30-day stroke/TIA/
amaurosis fugax were higher in the CAS group (13%) 
compared with the CEA group (7.7%), although the 
difference was not statistically significant. While there 
were 2 (1%) deaths within a 30-day period after the 
procedure in the CEA group, no death occurred in 
the CAS group. Previous studies have reported death 
or stroke rates of 6-9.6% for CAS and 3.2-6.3% for 
CEA.16-19 We suggest that the higher rate of short-term 
complications in our study may have resulted from 
differences in patient selection. Studies reported in the 
literature have not included the majority of patients 
with comorbid conditions and older than 75 years of 
age who are deemed high risk for surgical intervention.9 
In some studies enrolling high-risk patients, the rates 
of short-term complications have been as high as 
in our study.10,20 When we analyzed patients having 
complications, we noticed that 8 of 16 patients with 
short-term complications were above the age of 75 
years; furthermore, 50% of those who developed 
complication had a history of bypass surgery or 
comorbidities that create a thrombotic tendency such 
as chronic renal failure and atrial fibrillation. (Totally 
in CAS and CEA group 7 patients with chronic renal 
failure and 7 patients with atrial fibrillation). One 
additional cause may have been the differences in the 
definition and the time to emergence of complications 
in the other studies. We took into consideration all 
neurological complications that occurred in the first 
30 days and either recovered or resulted in permanent 
disability. Many studies, however, have included 
complications causing permanent disability, while a few 
of them included all events lasting for more than 24 
hours.21 While some studies have taken into account 
complications that lasted more than 24 hours after their 
onset, some others have taken complications lasting for 
48-76 hours, and some others did so in complications 
lasting even beyond 1 week.16,22
There are only a few studies comparing endovascular 
treatment and surgical treatment in asymptomatic and 
symptomatic patients. ARCHER study found a 30-day 
stroke rate of 3.8% in asymptomatic cases and 10.9% in 
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event.30 In a randomized controlled multicenter study, 
the restenosis rates of CEA 6.3% and CAS 6% have 
been reported.28 In the same study, being symptomatic 
did not affect restenosis rate, while female gender, DM, 
and HL were independent predictors of restenosis.28 
Another study found significantly greater restenosis rate 
in the endovascular treatment group compared with 
the surgery group.25 We found a higher, albeit non-
significant, restenosis rate in CEA group than the CAS 
group. Unlike literature data, we found a significantly 
higher restenosis rate in symptomatic cases in the CEA 
group than the CAS group.
The limitations of our study were the retrospective, 
the low number of patients and the relatively short 
follow-up. Another limitation of our study was that it 
was performed at a single center.
In conclusion, the superiority of CEA and CAS 
over medical therapy has now been proved. Short- and 
long-term complications of both treatment modalities 
and long-term restenosis development affect procedural 
success. New studies are needed to increase procedural 
success rates. 
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